The design
The BaCa design combines FOLR1 recognition with DR5 engagement in one antibody construct. In preclinical ovarian cancer systems, the study tested whether FOLR1 anchoring can help position DR5 agonism at tumor cells. The related invention belongs to a patent family that includes a U.S. grant in 2026.
FOLR1 binding supplies a tumor-associated anchor, while DR5 binding is intended to promote receptor clustering and apoptosis. The design rationale and observed preclinical responses are separate from clinical validation.
Evidence described publicly
The authors engineered and compared dual-specificity antibody formats, measured target binding and death signaling, and studied ovarian tumor models. The paper includes cell-based experiments and in vivo preclinical work; it does not describe an approved human therapy.
- One construct recognizes two targetsThe article describes antibody architecture combining FOLR1 and DR5 specificity.Source (external link)
- Anchoring changes response contextThe reported experiments test FOLR1-dependent localization of DR5 agonism in ovarian cancer systems.Source (external link)
- Preclinical antitumor activityThe paper reports cell and model-system effects that support further investigation of the format.Source (external link)
Record and status
Granted February 10, 2026. The earlier US 2020/0283537 publication belongs to the same family.
Proof of concept in laboratory and animal-model settings. The antibody is not represented here as an approved treatment. The U.S. grant and earlier application are members of one family, not separate inventions.
Read the official patent or technology record (external link)
Inventors and related research
Jogender Tushir-Singh, Sanchita Bhatnagar